by Gemma Escarré,
Amgen Iberia, the subsidiary of biotechnology multinational corporation Amgen and a member of CataloniaBio & HealthTech, increased its staff by 11% in 2018, for a total of 300 employees, after launching a new biosimilars unit, according to L’Econòmic. The company notes that these employees are highly qualified and that they promote equal pay for women and men.
Amgen first began working in Spain in 1990. Currently, the company has nearly 80 clinical trials under way in its various therapeutic areas and invests €18 million in R&D. Its drugs are used to treat serious diseases in cardiology, nephrology, oncohaematology and bone metabolism, among others, most with limited treatment options.
The Amgen Iberia headquarters are in the World Trade Center in Barcelona.
Photo: Fina Lladós, director general of Amgen Iberia since 2017 - © L’Econòmic, Josep Losada